Accretion Pharmaceuticals Ltd vs Medicamen Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Accretion Pharmaceuticals Ltd is ₹ 137.25 as of 12 Jun 15:30 . The P/E Ratio of Accretion Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 years The Market Cap of Accretion Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 years The revenue of Accretion Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Medicamen Biotech Ltd for the Mar '26 is ₹ 62.38 crore as compare to the Dec '25 revenue of ₹ 47.44 crore. This represent the growth of 31.49% The ebitda of Accretion Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Medicamen Biotech Ltd for the Mar '26 is ₹ 7.18 crore as compare to the Dec '25 ebitda of ₹ 4.91 crore. This represent the growth of 46.23% The net profit of Accretion Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 4.45 crore over 8 quarters. This represents a CAGR of 135.85% The Dividend Payout of Accretion Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 years .

About Accretion Pharmaceuticals Ltd

Accretion Pharmaceuticals was incorporated in year 2012, the Promoters Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati, came together to establish a pharmaceutical manufacturing unit, to provide health care products.
Thus, the foundation of 'Accretion Pharmaceuticals' was laid down, which was started as a Partnership Firm in the name of 'M/s Accretion Pharmaceuticals', pursuant to a deed of partnership dated December 18, 2012. The manufacturing facility which is currently located at Ahmedabad, in Sanand District of Gujarat, commenced its manufacturing operations in 2014.
Thereafter, the Partnership Firm was converted into a Limited Company in the name of 'Accretion Pharmaceuticals Limited' and a certificate of incorporation dated November 29, 2023 was issued by the Registrar of Companies, Central Registration Centre, for and on behalf of the jurisdictional Registrar of Companies.

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

FAQs for the comparison of Accretion Pharmaceuticals Ltd and Medicamen Biotech Ltd

Which company has a larger market capitalization, Accretion Pharmaceuticals Ltd or Medicamen Biotech Ltd?

Market cap of Accretion Pharmaceuticals Ltd is 152 Cr while Market cap of Medicamen Biotech Ltd is 311 Cr

What are the key factors driving the stock performance of Accretion Pharmaceuticals Ltd and Medicamen Biotech Ltd?

The stock performance of Accretion Pharmaceuticals Ltd and Medicamen Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Accretion Pharmaceuticals Ltd and Medicamen Biotech Ltd?

As of June 15, 2026, the Accretion Pharmaceuticals Ltd stock price is INR ₹137.25. On the other hand, Medicamen Biotech Ltd stock price is INR ₹229.45.

How do dividend payouts of Accretion Pharmaceuticals Ltd and Medicamen Biotech Ltd compare?

To compare the dividend payouts of Accretion Pharmaceuticals Ltd and Medicamen Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.